Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma

BACKGROUND: Programmed cell death receptor-1 (PD-1)-blocking antibodies are approved to treat metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) cases ineligible for curative surgery or radiation. Notwithstanding, some patients experience inadequate responses or severe immune-re...

Descripción completa

Detalles Bibliográficos
Autores principales: Clingan, Philip, Ladwa, Rahul, Brungs, Daniel, Harris, Dean Laurence, McGrath, Margaret, Arnold, Susan, Coward, Jermaine, Fourie, Samuel, Kurochkin, Andriy, Malan, Daniel R, Mant, Andrew, Sharma, Vinay, Shue, Hong, Tazbirkova, Andrea, Berciano-Guerrero, Miguel-Angel, Charoentum, Chaiyut, Dalle, Stéphane, Dechaphunkul, Arunee, Dudnichenko, Oleksandr, Koralewski, Piotr, Lugowska, Iwona, Montaudié, Henri, Muñoz-Couselo, Eva, Sriuranpong, Virote, Oliviero, James, Desai, Jayesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582968/
https://www.ncbi.nlm.nih.gov/pubmed/37848259
http://dx.doi.org/10.1136/jitc-2023-007637

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582968/
https://www.ncbi.nlm.nih.gov/pubmed/37848259
http://dx.doi.org/10.1136/jitc-2023-007637

Ejemplares similares